Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rexulti

- PMLiVE

Lundbeck’s Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

- PMLiVE

Lundbeck launches alcohol drug Selincro in Europe

Norway, Finland, Poland and the Baltic countries chosen as first markets

- PMLiVE

Otsuka files new TB candidate in Japan as shortages worsen

Delamanid shows promise in multi-drug resistant TB but supplies of rifampin are low

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

Otsuka’s Pletal has use restricted in Europe

EMA recommends drug only be used in limited group of patients with blood supply disorder

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Lundbeck’s alcohol dependency drug approved in Europe

Selincro is the first drug approved to reduce alcohol consumption

Product updates from Japan

New approvals and filings include drugs from Takeda, Otsuka, Chugai and Astellas

- PMLiVE

Former Nycomed CEO Hakan Bjorklund to chair Lundbeck

Mats Pettersson to step down in March

- PMLiVE

Lundbeck looks to new products as Lexapro slumps

Denmark-based pharma company reports flat sales during fourth quarter of 2012

- PMLiVE

Lundbeck launches Chorea Matters online resource

Includes recognising chorea education programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links